Induction Therapy for Acute Myelogenous Leukemia with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in “Response-Adapted” Sequence

  • R. Haas
  • A. Schneeweiß
  • B. Brado
  • B. Witt
  • W. Hunstein
  • F. Del Valle
  • M. Goebel
  • A. D. Ho
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

With conventional induction chemotherapy 47%–72% of adult patients with acute myelogenous leukemia (AML) achieve complete remission (CR). However, the probability of continuous CR ranges from 8% to 45% at 3 years [1]. Most of the chemotherapeutic protocols for induction treatment consist of cytosine arabinoside (Ara-C) combined with an anthracycline such as daunorubicin. One possibility to improve the induction remission rate is the administration of new agents with higher antileukemic activity. Furthermore, for patients not responding to the first-line chemotherapy, an alternate regimen with non-cross-resistant cytostatic drugs should be considered in the early phase of induction treatment.

Keywords

Oncol Etoposide Cytosine Anthracycline Cytarabine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Büchner T et al. (1987) Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML cooperative group. In: Büchner T et al. (eds) Acute leukemias. Springer, Berlin Heidelberg New York, pp 57–63 (Haematology and blood transfusion, vol 30 )CrossRefGoogle Scholar
  2. 2.
    Casazza AM, Pratesi G et al. (1980) Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 66: 549–564PubMedGoogle Scholar
  3. 3.
    Vogler WR, Velez-Garcia E et al. (1989) A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia. Semin Oncol 16 [Suppl 2]: 21–24PubMedGoogle Scholar
  4. 4.
    Berman E, Raymond V et al. (1989) Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol 16 [Suppl 2]: 30–34PubMedGoogle Scholar
  5. 5.
    Wiernik PH, Case DC Jr et al. (1989) A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Semin Oncol 16 [Suppl 2]: 25–29PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. Haas
    • 1
  • A. Schneeweiß
    • 1
  • B. Brado
    • 1
  • B. Witt
    • 1
  • W. Hunstein
    • 1
  • F. Del Valle
    • 2
  • M. Goebel
    • 3
  • A. D. Ho
    • 4
  1. 1.Department of Internal MedicineUniversity of HeidelbergGermany
  2. 2.Städtische Klinik OldenburgGermany
  3. 3.Farmitalia FreiburgGermany
  4. 4.Northeastern Ontario Oncology ProgramSudburyCanada

Personalised recommendations